NEW YORK, April 19, 2023 /PRNewswire/ -- The idiopathic pulmonary fibrosis market size is forecasted to increase by USD 1,360.99 million from 2022 to 2027, accelerating at a CAGR of 6.68%, according to a recent market study by Technavio. The growth of the market will be driven by the increasing prevalence of respiratory diseases, the growing geriatric population, and the increase in the number of smokers. Charts & data tables about market and segment sizes for the historic period (2017-2021) and the forecast period (2023-2027) are clearly illustrated in this report. Download the Sample Report
Vendor Analysis
The global idiopathic pulmonary fibrosis (IPF) market is fragmented. The market has several approved drugs for the symptomatic treatment of IPF. Owing to the strong prevalence of IPF and the need for highly effective drugs, several vendors are developing drugs to treat IPF. The strong pipeline of novel drugs and therapeutics is expected to pave the way for new entrants in the market during the forecast period. Hence, the market is expected to witness the launch of various novel drugs and therapeutics and the entry of a few new players during the forecast period. Some of the key vendors covered in the report include:
- Alembic Pharmaceuticals Ltd.
- Boehringer Ingelheim International GmbH
- Bristol Myers Squibb Co.
- Celix Pharma Ltd.
- Cipla Ltd.
- Daewoong Pharmaceutical Co. Ltd.
- F. Hoffmann La Roche Ltd.
- FibroGen Inc.
- Galapagos NV
- Galecto Inc.
- GNI Group Ltd.
- Horizon Therapeutics Plc
- Intas Pharmaceuticals Ltd.
- Jubilant Pharmova Ltd.
- Liminal BioSciences Inc.
Why Buy?
- Add credibility to strategy
- Analyzes competitor's offerings
- Get a holistic view of the market
Key Benefits for Industry Players & Stakeholders –
- The report offers information on the criticality of vendor inputs, including R&D, CAPEX, and technology.
- It also provides detailed analyses of the market's competitive landscape and vendors' product offerings.
- The report also provides a qualitative and quantitative analysis of vendors to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
Get a holistic market analysis of the global idiopathic pulmonary fibrosis market to
evaluate and develop growth strategies. Download the Sample
Market Segmentation:
The market is segmented by route of administration (oral and parenteral), drug class (systemic corticosteroids, immunosuppressants, tyrosine kinase inhibitors, and anti-fibrotic agents), and geography (North America, Europe, Asia, and Rest of World).
- The market growth in the oral segment will be significant over the forecast period. The oral route of administering drugs is most preferred by patients. These drugs are most patient-friendly and can be administered at home. They come in different forms such as tablets, capsules, and liquid solutions that can be swallowed. In addition, the presence of many approved oral medications available for the treatment of IPF drives the growth of the segment.
- North America will account for 35% of the market growth during the forecast period. The growth of the regional market is driven by the increasing prevalence of respiratory diseases, such as IPF. In addition, the increasing aging population, the rising number of smokers, and the strong presence of vendors focused on developing new drugs to treat patients suffering from IPF will drive the growth of the idiopathic pulmonary fibrosis market in North America.
Market Dynamics:
Key Drivers:
The market is driven by the increasing prevalence of respiratory diseases. Idiopathic pulmonary fibrosis is a fatal lung disease that affects thousands of people across the world. Exposure to occupational and environmental hazards, such as asbestos, silica, and metal dust particles, has increased the prevalence of the condition. The number of people diagnosed with IPF is increasing among all age groups and genders. The high prevalence of the condition has become a serious concern among healthcare providers and researchers. The prevalence of the condition is high among the aging population. If left untreated, IPF can result in disability, reduced productivity, and early retirement, leading to economic losses for individuals. All these factors are driving the growth of the market.
Major Trends:
The emergence of new patterns of IPF is a key trend in the market. The emergence of new patterns of IPF has been observed in patients worldwide. One of the new patterns observed among patients is the exacerbation of symptoms during viral infections, such as COVID-19. Researchers have found that viral infections could worsen the symptoms and lead to faster disease progression in patients. In addition, the advent of telehealth and remote monitoring has proven to be beneficial for IPF patients, as it allows them to receive medical care at their convenience. Such factors will positively influence the growth of the market during the forecast period.
Key Challenges:
Obstacles to reimbursement are identified as major challenges in the market. The prevalence of IPF is increasing significantly worldwide. It has increased the use of complex medical devices, such as nebulizers, aerosol inhalers, and oxygen systems. However, these devices are not covered by insurance and reimbursement plans. This could lead to a high economic burden on patients and their families. Such challenges will reduce the growth potential of the market during the forecast period.
Get instant lifetime access to 17,000+ market research reports along with world-class
market intelligence.
Technavio's SUBSCRIPTION platform
What are the key data covered in this idiopathic pulmonary fibrosis market report?
- CAGR of the market during the forecast period
- Detailed information on factors that will drive the growth of the idiopathic pulmonary fibrosis market between 2023 and 2027
- Precise estimation of the size of the idiopathic pulmonary fibrosis market and its contribution to the parent market
- Accurate predictions about upcoming trends and changes in consumer behavior
- Growth of the idiopathic pulmonary fibrosis market across North America, Europe, Asia, and Rest of World (ROW)
- A thorough analysis of the market's competitive landscape and detailed information about vendors
- Comprehensive analysis of factors that will challenge the growth of idiopathic pulmonary fibrosis market vendors
Related Reports:
The chronic obstructive pulmonary disease drugs market is estimated to grow at a CAGR of 6.09% between 2022 and 2027. The chronic obstructive pulmonary disease drugs market size is forecasted to increase by USD 6,654.49 million. The market is segmented by product (combination therapy and monotherapy), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and geography (North America, Europe, Asia, and Rest of World (ROW)).
The sinusitis drugs market is estimated to grow at a CAGR of 6.23% between 2022 and 2027. The size of the market is forecasted to increase by USD 801.39 million. The market is segmented by product (steroid nasal sprays, antibiotics, decongestants, and other drugs) and geography (North America, Europe, Asia, and Rest of World (ROW)).
Idiopathic Pulmonary Fibrosis Market Scope |
|
Report Coverage |
Details |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 6.68% |
Market growth 2023-2027 |
USD 1360.99 million |
Market structure |
Fragmented |
YoY growth 2022-2023 (%) |
6.41 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 35% |
Key countries |
US, Germany, UK, China, and Japan |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Alembic Pharmaceuticals Ltd., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celix Pharma Ltd., Cipla Ltd., Daewoong Pharmaceutical Co. Ltd., F. Hoffmann La Roche Ltd., FibroGen Inc., Galapagos NV, Galecto Inc., GNI Group Ltd., Horizon Therapeutics Plc, Intas Pharmaceuticals Ltd., Jubilant Pharmova Ltd., Liminal BioSciences Inc., MediciNova Inc., Merck and Co. Inc., Mission Therapeutics, Novartis AG, Shionogi and Co. Ltd., and United Therapeutics Corp. |
Market dynamics |
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Browse through Technavio's Health Care Market Reports
Table of contents:
1 Executive Summary
- 1.1 Market overview
- Exhibit 01: Executive Summary – Chart on Market Overview
- Exhibit 02: Executive Summary – Data Table on Market Overview
- Exhibit 03: Executive Summary – Chart on Global Market Characteristics
- Exhibit 04: Executive Summary – Chart on Market by Geography
- Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
- Exhibit 06: Executive Summary – Chart on Market Segmentation by Drug Class
- Exhibit 07: Executive Summary – Chart on Incremental Growth
- Exhibit 08: Executive Summary – Data Table on Incremental Growth
- Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
2 Market Landscape
- 2.1 Market ecosystem
- Exhibit 10: Parent market
- Exhibit 11: Market Characteristics
3 Market Sizing
- 3.1 Market definition
- Exhibit 12: Offerings of vendors included in the market definition
- 3.2 Market segment analysis
- Exhibit 13: Market segments
- 3.3 Market size 2022
- 3.4 Market outlook: Forecast for 2022-2027
- Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
- Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
- Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
4 Historic Market Size
- 4.1 Global idiopathic pulmonary fibrosis market 2017 - 2021
- Exhibit 18: Historic Market Size – Data Table on Global idiopathic pulmonary fibrosis market 2017 - 2021 ($ million)
- 4.2 Route of Administration Segment Analysis 2017 - 2021
- Exhibit 19: Historic Market Size – Route of Administration Segment 2017 - 2021 ($ million)
- 4.3 Drug Class Segment Analysis 2017 - 2021
- Exhibit 20: Historic Market Size – Drug Class Segment 2017 - 2021 ($ million)
- 4.4 Geography Segment Analysis 2017 - 2021
- Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
- 4.5 Country Segment Analysis 2017 - 2021
- Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)
5 Five Forces Analysis
- 5.1 Five forces summary
- Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
- 5.2 Bargaining power of buyers
- Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
- 5.3 Bargaining power of suppliers
- Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
- 5.4 Threat of new entrants
- Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
- 5.5 Threat of substitutes
- Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
- 5.6 Threat of rivalry
- Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
- 5.7 Market condition
- Exhibit 29: Chart on Market condition - Five forces 2022 and 2027
6 Market Segmentation by Route of Administration
- 6.1 Market segments
- Exhibit 30: Chart on Route of Administration - Market share 2022-2027 (%)
- Exhibit 31: Data Table on Route of Administration - Market share 2022-2027 (%)
- 6.2 Comparison by Route of Administration
- Exhibit 32: Chart on Comparison by Route of Administration
- Exhibit 33: Data Table on Comparison by Route of Administration
- 6.3 Oral - Market size and forecast 2022-2027
- Exhibit 34: Chart on Oral - Market size and forecast 2022-2027 ($ million)
- Exhibit 35: Data Table on Oral - Market size and forecast 2022-2027 ($ million)
- Exhibit 36: Chart on Oral - Year-over-year growth 2022-2027 (%)
- Exhibit 37: Data Table on Oral - Year-over-year growth 2022-2027 (%)
- 6.4 Parenteral - Market size and forecast 2022-2027
- Exhibit 38: Chart on Parenteral - Market size and forecast 2022-2027 ($ million)
- Exhibit 39: Data Table on Parenteral - Market size and forecast 2022-2027 ($ million)
- Exhibit 40: Chart on Parenteral - Year-over-year growth 2022-2027 (%)
- Exhibit 41: Data Table on Parenteral - Year-over-year growth 2022-2027 (%)
- 6.5 Market opportunity by Route of Administration
- Exhibit 42: Market opportunity by Route of Administration ($ million)
- Exhibit 43: Data Table on Market opportunity by Route of Administration ($ million)
7 Market Segmentation by Drug Class
- 7.1 Market segments
- Exhibit 44: Chart on Drug Class - Market share 2022-2027 (%)
- Exhibit 45: Data Table on Drug Class - Market share 2022-2027 (%)
- 7.2 Comparison by Drug Class
- Exhibit 46: Chart on Comparison by Drug Class
- Exhibit 47: Data Table on Comparison by Drug Class
- 7.3 Systemic corticosteroids - Market size and forecast 2022-2027
- Exhibit 48: Chart on Systemic corticosteroids - Market size and forecast 2022-2027 ($ million)
- Exhibit 49: Data Table on Systemic corticosteroids - Market size and forecast 2022-2027 ($ million)
- Exhibit 50: Chart on Systemic corticosteroids - Year-over-year growth 2022-2027 (%)
- Exhibit 51: Data Table on Systemic corticosteroids - Year-over-year growth 2022-2027 (%)
- 7.4 Immunosuppressants - Market size and forecast 2022-2027
- Exhibit 52: Chart on Immunosuppressants - Market size and forecast 2022-2027 ($ million)
- Exhibit 53: Data Table on Immunosuppressants - Market size and forecast 2022-2027 ($ million)
- Exhibit 54: Chart on Immunosuppressants - Year-over-year growth 2022-2027 (%)
- Exhibit 55: Data Table on Immunosuppressants - Year-over-year growth 2022-2027 (%)
- 7.5 Tyrosine kinase inhibitors - Market size and forecast 2022-2027
- Exhibit 56: Chart on Tyrosine kinase inhibitors - Market size and forecast 2022-2027 ($ million)
- Exhibit 57: Data Table on Tyrosine kinase inhibitors - Market size and forecast 2022-2027 ($ million)
- Exhibit 58: Chart on Tyrosine kinase inhibitors - Year-over-year growth 2022-2027 (%)
- Exhibit 59: Data Table on Tyrosine kinase inhibitors - Year-over-year growth 2022-2027 (%)
- 7.6 Anti-fibrotic agents - Market size and forecast 2022-2027
- Exhibit 60: Chart on Anti-fibrotic agents - Market size and forecast 2022-2027 ($ million)
- Exhibit 61: Data Table on Anti-fibrotic agents - Market size and forecast 2022-2027 ($ million)
- Exhibit 62: Chart on Anti-fibrotic agents - Year-over-year growth 2022-2027 (%)
- Exhibit 63: Data Table on Anti-fibrotic agents - Year-over-year growth 2022-2027 (%)
- 7.7 Market opportunity by Drug Class
- Exhibit 64: Market opportunity by Drug Class ($ million)
- Exhibit 65: Data Table on Market opportunity by Drug Class ($ million)
8 Customer Landscape
- 8.1 Customer landscape overview
- Exhibit 66: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
9 Geographic Landscape
- 9.1 Geographic segmentation
- Exhibit 67: Chart on Market share by geography 2022-2027 (%)
- Exhibit 68: Data Table on Market share by geography 2022-2027 (%)
- 9.2 Geographic comparison
- Exhibit 69: Chart on Geographic comparison
- Exhibit 70: Data Table on Geographic comparison
- 9.3 North America - Market size and forecast 2022-2027
- Exhibit 71: Chart on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 72: Data Table on North America - Market size and forecast 2022-2027 ($ million)
- Exhibit 73: Chart on North America - Year-over-year growth 2022-2027 (%)
- Exhibit 74: Data Table on North America - Year-over-year growth 2022-2027 (%)
- 9.4 Europe - Market size and forecast 2022-2027
- Exhibit 75: Chart on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 76: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
- Exhibit 77: Chart on Europe - Year-over-year growth 2022-2027 (%)
- Exhibit 78: Data Table on Europe - Year-over-year growth 2022-2027 (%)
- 9.5 Asia - Market size and forecast 2022-2027
- Exhibit 79: Chart on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 80: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
- Exhibit 81: Chart on Asia - Year-over-year growth 2022-2027 (%)
- Exhibit 82: Data Table on Asia - Year-over-year growth 2022-2027 (%)
- 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
- Exhibit 83: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 84: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
- Exhibit 85: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- Exhibit 86: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
- 9.7 US - Market size and forecast 2022-2027
- Exhibit 87: Chart on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 88: Data Table on US - Market size and forecast 2022-2027 ($ million)
- Exhibit 89: Chart on US - Year-over-year growth 2022-2027 (%)
- Exhibit 90: Data Table on US - Year-over-year growth 2022-2027 (%)
- 9.8 China - Market size and forecast 2022-2027
- Exhibit 91: Chart on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 92: Data Table on China - Market size and forecast 2022-2027 ($ million)
- Exhibit 93: Chart on China - Year-over-year growth 2022-2027 (%)
- Exhibit 94: Data Table on China - Year-over-year growth 2022-2027 (%)
- 9.9 Japan - Market size and forecast 2022-2027
- Exhibit 95: Chart on Japan - Market size and forecast 2022-2027 ($ million)
- Exhibit 96: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
- Exhibit 97: Chart on Japan - Year-over-year growth 2022-2027 (%)
- Exhibit 98: Data Table on Japan - Year-over-year growth 2022-2027 (%)
- 9.10 Germany - Market size and forecast 2022-2027
- Exhibit 99: Chart on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 100: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
- Exhibit 101: Chart on Germany - Year-over-year growth 2022-2027 (%)
- Exhibit 102: Data Table on Germany - Year-over-year growth 2022-2027 (%)
- 9.11 UK - Market size and forecast 2022-2027
- Exhibit 103: Chart on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 104: Data Table on UK - Market size and forecast 2022-2027 ($ million)
- Exhibit 105: Chart on UK - Year-over-year growth 2022-2027 (%)
- Exhibit 106: Data Table on UK - Year-over-year growth 2022-2027 (%)
- 9.12 Market opportunity by geography
- Exhibit 107: Market opportunity by geography ($ million)
- Exhibit 108: Data Tables on Market opportunity by geography ($ million)
10 Drivers, Challenges, and Trends
- 10.1 Market drivers
- 10.2 Market challenges
- 10.3 Impact of drivers and challenges
- Exhibit 109: Impact of drivers and challenges in 2022 and 2027
- 10.4 Market trends
11 Vendor Landscape
- 11.1 Overview
- 11.2 Vendor landscape
- Exhibit 110: Overview on Criticality of inputs and Factors of differentiation
- 11.3 Landscape disruption
- Exhibit 111: Overview on factors of disruption
- 11.4 Industry risks
- Exhibit 112: Impact of key risks on business
12 Vendor Analysis
- 12.1 Vendors covered
- Exhibit 113: Vendors covered
- 12.2 Market positioning of vendors
- Exhibit 114: Matrix on vendor position and classification
- 12.3 AstraZeneca Plc
- Exhibit 115: AstraZeneca Plc - Overview
- Exhibit 116: AstraZeneca Plc - Product / Service
- Exhibit 117: AstraZeneca Plc - Key news
- Exhibit 118: AstraZeneca Plc - Key offerings
- 12.4 Boehringer Ingelheim International GmbH
- Exhibit 119: Boehringer Ingelheim International GmbH - Overview
- Exhibit 120: Boehringer Ingelheim International GmbH - Business segments
- Exhibit 121: Boehringer Ingelheim International GmbH - Key news
- Exhibit 122: Boehringer Ingelheim International GmbH - Key offerings
- Exhibit 123: Boehringer Ingelheim International GmbH - Segment focus
- 12.5 Bristol Myers Squibb Co.
- Exhibit 124: Bristol Myers Squibb Co. - Overview
- Exhibit 125: Bristol Myers Squibb Co. - Product / Service
- Exhibit 126: Bristol Myers Squibb Co. - Key news
- Exhibit 127: Bristol Myers Squibb Co. - Key offerings
- 12.6 Cipla Ltd.
- Exhibit 128: Cipla Ltd. - Overview
- Exhibit 129: Cipla Ltd. - Business segments
- Exhibit 130: Cipla Ltd. - Key news
- Exhibit 131: Cipla Ltd. - Key offerings
- Exhibit 132: Cipla Ltd. - Segment focus
- 12.7 F. Hoffmann La Roche Ltd.
- Exhibit 133: F. Hoffmann La Roche Ltd. - Overview
- Exhibit 134: F. Hoffmann La Roche Ltd. - Business segments
- Exhibit 135: F. Hoffmann La Roche Ltd. - Key news
- Exhibit 136: F. Hoffmann La Roche Ltd. - Key offerings
- Exhibit 137: F. Hoffmann La Roche Ltd. - Segment focus
- 12.8 FibroGen Inc.
- Exhibit 138: FibroGen Inc. - Overview
- Exhibit 139: FibroGen Inc. - Product / Service
- Exhibit 140: FibroGen Inc. - Key offerings
- 12.9 Galapagos NV
- Exhibit 141: Galapagos NV - Overview
- Exhibit 142: Galapagos NV - Product / Service
- Exhibit 143: Galapagos NV - Key offerings
- 12.10 GNI Group Ltd.
- Exhibit 144: GNI Group Ltd. - Overview
- Exhibit 145: GNI Group Ltd. - Product / Service
- Exhibit 146: GNI Group Ltd. - Key offerings
- 12.11 Horizon Therapeutics Plc
- Exhibit 147: Horizon Therapeutics Plc - Overview
- Exhibit 148: Horizon Therapeutics Plc - Business segments
- Exhibit 149: Horizon Therapeutics Plc - Key news
- Exhibit 150: Horizon Therapeutics Plc - Key offerings
- Exhibit 151: Horizon Therapeutics Plc - Segment focus
- 12.12 Jubilant Pharmova Ltd.
- Exhibit 152: Jubilant Pharmova Ltd. - Overview
- Exhibit 153: Jubilant Pharmova Ltd. - Business segments
- Exhibit 154: Jubilant Pharmova Ltd. - Key news
- Exhibit 155: Jubilant Pharmova Ltd. - Key offerings
- Exhibit 156: Jubilant Pharmova Ltd. - Segment focus
- 12.13 Liminal BioSciences Inc.
- Exhibit 157: Liminal BioSciences Inc. - Overview
- Exhibit 158: Liminal BioSciences Inc. - Product / Service
- Exhibit 159: Liminal BioSciences Inc. - Key offerings
- 12.14 MediciNova Inc.
- Exhibit 160: MediciNova Inc. - Overview
- Exhibit 161: MediciNova Inc. - Product / Service
- Exhibit 162: MediciNova Inc. - Key offerings
- 12.15 Novartis AG
- Exhibit 163: Novartis AG - Overview
- Exhibit 164: Novartis AG - Business segments
- Exhibit 165: Novartis AG - Key offerings
- Exhibit 166: Novartis AG - Segment focus
- 12.16 Shionogi and Co. Ltd.
- Exhibit 167: Shionogi and Co. Ltd. - Overview
- Exhibit 168: Shionogi and Co. Ltd. - Product / Service
- Exhibit 169: Shionogi and Co. Ltd. - Key offerings
- 12.17 United Therapeutics Corp.
- Exhibit 170: United Therapeutics Corp. - Overview
- Exhibit 171: United Therapeutics Corp. - Product / Service
- Exhibit 172: United Therapeutics Corp. - Key offerings
13 Appendix
- 13.1 Scope of the report
- 13.2 Inclusions and exclusions checklist
- Exhibit 173: Inclusions checklist
- Exhibit 174: Exclusions checklist
- 13.3 Currency conversion rates for US$
- Exhibit 175: Currency conversion rates for US$
- 13.4 Research methodology
- Exhibit 176: Research methodology
- Exhibit 177: Validation techniques employed for market sizing
- Exhibit 178: Information sources
- 13.5 List of abbreviations
- Exhibit 179: List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article